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ABSTRACT
Prior studies implicate type 1 IGF receptor (IGF-1R) in mediating chemo-
resistance. Here, we investigated whether IGF-1R influences response to temozolomide 
(TMZ), which generates DNA adducts that are removed by O6-methylguanine-DNA 
methyltransferase (MGMT), or persist causing replication-associated double-strand 
breaks (DSBs). Initial assessment in 10 melanoma cell lines revealed that TMZ 
resistance correlated with MGMT expression (r = 0.79, p = 0.009), and in MGMT-
proficient cell lines, with phospho-IGF-1R (r = 0.81, p = 0.038), suggesting that 
TMZ resistance associates with IGF-1R activation. Next, effects of IGF-1R inhibitors 
(IGF-1Ri) AZ3801 and linsitinib (OSI-906) were tested on TMZ-sensitivity, cell 
cycle progression and DSB induction. IGF-1Ri sensitized BRAF wild-type and mutant 
melanoma cells to TMZ in vitro, an effect that was independent of MGMT. Cells 
harboring wild-type p53 were more sensitive to IGF-1Ri, and showed schedule-
dependent chemo-sensitization that was most effective when IGF-1Ri followed TMZ. 
This sequence sensitized to clinically-achievable TMZ concentrations and enhanced 
TMZ-induced apoptosis. Simultaneous or prior IGF-1Ri caused less effective chemo-
sensitization, associated with increased G1 population and reduced accumulation 
of TMZ-induced DSBs. Clinically relevant sequential (TMZ ã IGF-1Ri) treatment was 
tested in mice bearing A375M (V600E BRAF, wild-type p53) melanoma xenografts, 
achieving peak plasma/tumor IGF-1Ri levels comparable to clinical Cmax, and 
inducing extensive intratumoral apoptosis. TMZ or IGF-1Ri caused minor inhibition 
of tumor growth (gradient reduction 13%, 25% respectively), while combination 
treatment caused supra-additive growth delay (72%) that was significantly different 
from control (p < 0.01), TMZ (p < 0.01) and IGF-1Ri (p < 0.05) groups. These data 
highlight the importance of scheduling when combining IGF-1Ri and other targeted 
agents with drugs that induce replication-associated DNA damage.
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INTRODUCTION
Metastatic melanoma is highly chemo-resistant: 
dacarbazine or temozolomide (TMZ) induce responses in 
<20% of patients, with very limited survival benefit [1, 2]. 
Approximately 40–50% of melanomas harbour activating 
mutations in the RAS-RAF axis, commonly V600E BRAF 
[3]. The outlook has improved significantly following 
development of novel forms of immunotherapy and 
mutant BRAF inhibitors, although responses to the latter 
are often brief, with early emergence of resistance [4, 5].
Type 1 insulin-like growth factor receptor (IGF-1R) 
is frequently up-regulated in cancers including melanoma, 
and promotes proliferation and cell survival [6, 7]. IGF-
1R expression has been associated with an aggressive 
clinical course and resistance to chemotherapy and 
targeted agents [8–10]. We previously showed that IGF-
1R depletion blocks survival of BRAF mutant and wild-
type (WT) melanoma cells, and enhances chemosensitivity 
[11]. Recently, we reported that IGF-1R depletion or 
inhibition delay repair of radiation-induced DNA double-
strand breaks (DSBs), with evidence of impaired repair 
by both non-homologous end-joining and homologous 
recombination (HR) [12, 13]. Many cytotoxic drugs cause 
DNA damage that is induced during DNA replication, 
requiring HR for repair [14]. Initiation of HR is very 
tightly coupled to cell cycle regulation, itself known to 
be influenced by IGFs [7, 15]. Therefore, as a tool to 
probe the relationship between IGF-1R and induction 
of replication-associated DNA damage, we examined 
responses to TMZ, a methylating agent used to treat 
glioblastoma multiforme and melanoma [16].
We tested two ATP-competitive IGF-1R tyrosine 
kinase inhibitors (IGF-1Ri): preclinical compound 
AZ12253801 (AZ3801), used in our study of effects 
of IGF-1Ri on the DNA damage response [13], and 
OSI-906 (linsitinib), developed for clinical evaluation 
[17–19]. AZ3801 has ~10 fold selectivity over the 
insulin receptor (INSR), with IC50 values for inhibition 
of IGF-1R of 2.1 nM and INSR 19 nM [13]. OSI-906 is 
~2-fold more potent against IGF-1R than INSR (IC50 
values 35 nM and 75 nM respectively), and recently 
completed Phase I trials using intermittent or continuous 
schedules [17–19]. Our data show an association between 
WT p53 status and sensitivity to IGF-1Ri, reveal that 
IGF-1R activation correlates with resistance to TMZ, and 
show that significant enhancement of chemo-sensitivity 
is induced by a sequential (TMZ → IGF-1Ri) schedule. 
In contrast, IGF-1Ri pre-treatment causes less effective 
chemo-sensitization, and we show for the first time that 
pre-inhibiting IGF-1R induces cell cycle delay associated 
with reduced yield of toxic chemotherapy-induced 
DNA damage. These findings have clear relevance to 
the design of future trials of IGF axis inhibitors with 
chemotherapy.
RESULTS
IGF-1R phosphorylation associates with 
resistance of melanoma cell lines to TMZ
In a human melanoma cell line panel we assessed 
levels and activation of IGF-1R and its effectors AKT 
and ERKs, and expression of O6-methylguanine-DNA 
methyltransferase (MGMT) that removes the most 
toxic TMZ-induced DNA adduct, O6-methyguanine 
(O6-meG; [16]; Figure 1A). All cell lines expressed IGF-
1R, with variable receptor phosphorylation. Reflecting 
the frequency of RAS-RAF activation [3], phospho-ERK 
was detectable in all cell lines except CHL1 that harbors 
WT BRAF/NRAS (Table 1). In a first approach to test the 
relationship between IGF-1R and chemo-resistance, we 
evaluated TMZ in viability assays (Figure 1B, Table 1). 
All cell lines were relatively TMZ-resistant, with GI50 
values 155–950 μM, above 60 μM, the clinically-
achievable Cmax [1]. MGMT-deficient SKmel23, 
A2058 and HMCB were relatively sensitive (TMZ GI50 
155 - 215 μM), and MGMT-positive cell lines more 
resistant (TMZ GI50 ≥ 250 μM; Table 1). TMZ GI50 values 
significantly correlated with MGMT expression (r = 0.79, 
p = 0.009; Figure 1C, upper panel), and showed borderline 
correlation with IGF-1R protein levels (r = 0.64, p = 0.052, 
Supplementary Figure S1A). In 7 MGMT proficient cell 
lines, there was significant correlation between TMZ GI50 
and phospho-IGF-1R (r = 0.81, p = 0.038; Figure 1C 
lower), suggesting association between activated IGF-1R 
and intrinsic TMZ resistance. These results prompted us to 
test effects of IGF-1Ri on growth and chemo-resistance.
Cells that harbor WT p53 are more sensitive to 
IGF-1R inhibition
Initial experiments tested sensitivity to IGF-1R 
inhibitor OSI-906, which was shown to be capable of 
blocking IGF-1R activation for ≥72 hr in A375M cells 
(Figure 1D). In the cell line panel, OSI-906 caused variable 
concentration-dependent inhibition of melanoma cell 
viability (Figure 1E), with GI50 values from the nanomolar 
to low micromolar range (Table 1). These are clinically 
achievable concentrations: continuous OSI-906 dosing at 
150 mg BID achieves plasma levels of ~1000–2000  ng/
ml (2.4–4.8 μM), while 600 mg OSI-906 intermittently 
achieves Cmax of ~8000 ng/ml (~20 μM), remaining at 
24 hr above 1 μM, predicted to be required for efficacy 
[18, 19]. Here, there was no correlation between OSI-906 
sensitivity and total/activated IGF-1R in the melanoma 
cell lines, and no evidence that downstream pathway 
activation due to PTEN loss, BRAF or NRAS mutation 
was associated with IGF-1Ri resistance, consistent with 
our previous data using IGF1R gene silencing [11]. We 
noted that the three most IGF-1Ri-resistant cell lines 
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(GI50 ~10 μM or greater) harbored mutant p53 (Table 1). 
Given that these cell lines are genetically heterogeneous, 
we tested the relationship between p53 and response to 
IGF-1Ri in p53-null B231 cells, in which expression of 
WT p53 was induced by doxycycline (Figure 1F; [20]. WT 
p53 is reported to suppress IGF-1R expression [21], but 
did not influence IGF-1R levels here. The p53 null cells 
were relatively resistant to OSI-906 (GI50 > 1 μM), and 
doxycycline-treated cells more sensitive (GI50 116 nM), 
indicating ≥8-fold sensitization to OSI-906. Thus in both 
this isogenic model and the melanoma cell lines, lack of 
WT p53 correlated with relative resistance to IGF-1Ri.
IGF-1R inhibition induces MGMT-independent 
sensitization of BRAF WT and mutant 
melanoma cells to TMZ
We next assessed whether IGF-1Ri modifies 
response to TMZ in vitro, testing OSI-906 and AZ3801 
in BRAF mutant A375M and BRAF WT CHL1, 
relatively TMZ-resistant (TMZ GI50 800 μM) and 
sensitive (250 μM), respectively (Table 1). Like OSI-
906, AZ3801 caused dose-dependent IGF-1R inhibition 
for up to 72 hr (Figure 2A). On testing responses 
to TMZ alone or with IGF-1Ri in survival assays, 
both OSI-906 and AZ3801 induced dose-dependent 
TMZ sensitization in each cell line (Figure 2B, 2C, 
Supplementary Figure 1B–1C). The effect size was 
similar with both inhibitors, and comparable to TMZ-
sensitization we previously reported in IGF-1R-depleted 
melanoma cells [11], supporting the contention that 
sensitization was related to IGF-1R inhibition. To 
explore the molecular basis for chemosensitization, we 
performed caspase 3/7 activity assays (Figure 2D) and 
western blotting for PARP cleavage (Supplementary 
Figure S2A), detecting increased TMZ-induced 
apoptosis in IGF-1R inhibited cells after 24–48 hr. 
However, the effect of AZ3801 on apoptosis did 
Figure 1: IGF axis association with TMZ resistance and p53 status. A. Whole cell extracts analyzed by western blotting. Similar 
results were obtained in a second set of independent lysates. B. Cells were treated with TMZ or vehicle, after 5 days CellTiter Glo viability 
assays were performed and data were expressed as % viability in TMZ-untreated cultures. Graphs: pooled results from 2 independent 
assays (6 data points) expressed as mean ± SEM % viability. C. Correlation between TMZ GI50 and upper: MGMT; lower: phospho-IGF-
1R, quantified from western blots in A, corrected for actin loading. D. Serum-starved A375M cells treated with: upper, OSI-906 for 1 hr; 
lower: 1 μM OSI-906 for 1–72 hr, and in the final 15 min with 50 nM IGF-1. E. Cells were treated with OSI-906 or vehicle, and after 5 days 
viability assayed as B). F. B231 cells treated with solvent or 2 μg/ml doxycycline for 24 hr, and lysed for western blot (inset) or treated with 
solvent or OSI-906 as E) and viability assayed after 5 days. Graph: data from n = 3 assays; bars, SEM. GI50 values were > 1 μM in p53 null 
cells, 116 nM in p53-positive cells.
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not increase with TMZ concentration, unlike the 
pattern of chemo-sensitization (Figure 2B–2C), 
suggesting that chemo-sensitization was unlikely to 
be wholly attributable to apoptosis induction at these 
early time-points. Therefore, we next investigated 
whether IGF-1R influences repair of TMZ-induced DNA 
damage.
The most toxic alkylated base lesion produced by 
TMZ is O6-meG, which can be directly repaired by methyl 
group transfer to a cysteine residue in the MGMT active 
site pocket [16]. MGMT downregulation is associated, 
as here (Figure 1C upper), with melanoma sensitivity to 
TMZ in vitro, although not clinically [22]. Other base 
lesions include N7-meG, the commonest TMZ-induced 
lesion, which undergoes spontaneous depurination to 
generate toxic apurinic (AP) sites, and N3meA, which 
is intrinsically cytotoxic. Both lesions can be excised 
by 3-alkyladeinine DNA glycosylase (AAG) [23]. To 
test whether IGF-1Ri influences MGMT and AAG, we 
first performed chemo-sensitivity assays in MGMT-
null SKmel23 cells, which are highly TMZ sensitive, 
but even so IGF-1R induced further sensitization 
(Figure 2E). Secondly, in MGMT-proficient CHL1 and 
A375M, MGMT activity/expression was unaffected 
by IGF-1Ri (Supplementary Figure 2B left panel, 2C). 
MGMT assay specificity was supported by abolition 
of MGMT activity in CHL1 and A375M by MGMT 
substrate analogue O6-Benzylguanine (O6BG), and by 
undetectable MGMT activity in SKmel23 (Supplementary 
Figure 2B left panel). Similarly, IGF-1Ri did not influence 
AAG activity or TMZ-induced O6-meG or N7-meG 
adducts (Supplementary Figure 2B right panel, 2D–2E). 
Furthermore, AZ3801 was capable of sensitizing to TMZ 
in CHL1 cells in which MGMT was inhibited by O6BG 
(Figure 2F). These results suggest that with respect to 
TMZ-sensitization, IGF-1R does not function in the same 
pathway as MGMT.
IGF-1R inhibition induces schedule-dependent 
chemo-sensitization of melanoma cells
If MGMT levels are inadequate, O6-meG persists 
and undergoes post-replicative mispairing to form G:T 
pairs that are substrates for mismatch repair. Repeated 
‘futile cycles’ of exonuclease activity and mispairing 
lead to extension of single-stranded gaps, resulting after 
≥2 rounds of replication in replication fork collapse and 
formation of DSBs [16]. Given that IGFs are well-known 
to promote cell cycle progression [7], it is plausible that 
inhibiting this function could influence accumulation 
of replication-associated DSBs. As an initial step to 
investigate interactions between the IGF axis and 
TMZ-response, we tested whether chemo-sensitization 
is influenced by sequencing IGF-1Ri with respect to 
TMZ. Based on initial chemo-sensitivity data (Figure 
2B–2C), we first tested each drug separately to choose 
concentrations for combination experiments, using TMZ 
at 100–250 μM, and OSI-906 at 300–1000 nM in CHL1 
and 30–300 nM in A375M; 1000 nM was too toxic in 
these cells for combination testing (Figure 3A–3B). We 
next tested whether chemo-sensitization is influenced 
by sequencing of IGF-1Ri, using schedules illustrated in 
Figure 3C. There was no evidence of antagonism (ie no 
Table 1: Characteristics of melanoma cell line panel
Cell line BRAF NRAS PTEN p53 Other
GI50
TMZ μM OSI-906 nM
CHL1 WT WT WT Mut CDKN2A 250 9200
SKmel2 WT Mut WT Mut – 250 3420
SKmel23 WT WT Del WT – 155 5960
SKmel28 Mut WT Mut Mut EGFR 950 >10000
A375 Mut WT WT WT CDKN2A 280 800
A375M Mut WT WT WT CDKN2A 800 150
A2058 Mut WT Mut Mut CDKN2A 200 >10000
HMCB WT Mut WT Mut – 215 5880
501mel Mut WT WT Mut CTNNB1 400 60
COLO858 Mut WT WT WT – 380 ND
Genotypes from http://www.sanger.ac.uk/genetics/CGP/CellLines/, www-p53.iarc.fr/CellLineCriteria.asp and references 
[30, 51, 52]. Data from cell viability assays (Figure 1B, 1E) were curve-fitted to interpolate TMZ and OSI-906 GI50 values.
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increase in TMZ SF50 in OSI-906-treated cells), although 
cells pre-treated with 30 nM OSI-906 were no more 
TMZ-sensitive than controls. With this exception, IGF-
1R-inhibited cells showed dose-dependent sensitization 
to TMZ (Figure 3D), most effectively when OSI-906 
was applied 24 hr after TMZ, compared with cells that 
were pre-treated or simultaneously-treated. Notably, post-
treatment with 300 nM OSI-906 achieved TMZ SF50 of 
45 μM (Figure 3D, right panel), representing > 5.5 fold 
sensitization compared with control (OSI-906-untreated) 
cells. This SF50 value is below the Cmax of TMZ (~11 μg/
ml, ~60 μM) administered clinically as a single agent [1]. 
Equivalent experiments in CHL1 cells confirmed TMZ-
sensitization, but there was no difference in efficacy when 
IGF-1Ri was added before, concurrently or after TMZ 
(Supplementary Figure 3A–3B).
IGF-1R inhibition influences cell cycle 
distribution and DNA damage induction  
post-TMZ
Aiming to understand the basis for schedule-
dependent chemo-sensitization of A375M cells and the 
lack of sequence variation in CHL1, we investigated 
changes in cell cycle distribution. After 24 hr exposure 
to OSI-906 or AZ3801, there was increase in G1 and 
reduction in S phase fraction (Supplementary Figure S4A–
S4B), consistent with the ability of IGFs to promote G1 
to S transition [7]. TMZ-treated cells showed an increased 
G2 population and progressive reduction in S-phase, also 
evident upon combination treatment and most pronounced 
at 72 hr (Supplementary Figure S4A–S4B). Fixing on 
this 72 hr post-TMZ time-point, we tested effects of 
Figure 2: IGF-1R inhibition induces MGMT-independent sensitization of BRAF WT and mutant melanoma cells to 
TMZ. A. Serum-starved CHL1 cells treated with: upper, AZ3801 for 1 hr; lower, 30 nM AZ12253801 for 1–72 hr, and with IGF-1 as 
Figure 1D. B. CHL1 and C. A375M cells treated with TMZ alone or with AZ3801 or OSI-906. Graphs: mean ± SEM % cell survival from 
n = 3 independent assays in each cell line. IGF-1Ri-treated cells were sensitized to TMZ (*p < 0.05, **p < 0.01, ***p < 0.001). D. Graphs: 
mean ± SEM caspase activity (% signal in solvent-treated controls) from n = 2 independent assays in CHL1 cells, each with triplicate 
samples. AZ3801 enhanced apoptosis after 24 hr (upper) and 48 hr (lower; *p < 0.05, **p < 0.01, ***p < 0.001). E. SKmel23 cells treated 
with solvent or 50 μM TMZ alone or with 75 nM AZ3801. Graph: mean ± SEM % survival from n = 3 assays (*p < 0.05). The sensitivity 
of SKmel23 to IGF-1Ri precluded testing of AZ3801 > 75 nM. F. CHL1 cells pre-treated for 2 hr with 10 μM O6BG prior to TMZ alone 
or with AZ3801. Graph: pooled data from n = 2 survival assays from which were derived TMZ SF50 values, shown in legend. In cultures 
treated with 300 μM TMZ, O6BG suppressed survival of AZ3801-untreated controls from 59 ± 3% to 24 ± 4% (p < 0.001), with 50 nM 
AZ3801 from 34 ± 4% to 13 ± 2% ( p < 0.001), and 100 nM AZ3801 from 16 ± 4% to 2 ± 0.5% ( p < 0.05).
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altering the sequence of IGF-1Ri with respect to TMZ, 
using the same schedule (Figure 3C) as for chemo-
sensitivity testing. These experiments used 300 nM 
OSI-906, confirmed to inhibit IGF signaling in both cell 
lines (Figure 4A). In A375M, TMZ-induced reduction in 
S-phase and increase in G2 was unaffected by IGF-1R 
pre-, co- or post- inhibition (Figure 4B–4C). However, 
the G1 population was significantly increased when 
IGF-1R was pre- or co- inhibited, compared with TMZ 
alone and with IGF-1R post-inhibition (Figure 4C). TMZ 
induced appearance of non-cycling S-phase cells with 
DNA content between 2N and 4N but without BrdU 
incorporation (Figure 4C), suggesting intra-S checkpoint 
activation [24]. This population was reduced by IGF-1Ri; 
further work is required to test whether this represents loss 
of checkpoint integrity. We noted appearance of pre-G1 
(likely apoptotic) DNA content, significantly greater in 
IGF-1R post-inhibited cells, correlating with the pattern 
of chemo-sensitization (Figure 3D). In contrast, IGF-
1Ri-treated CHL1 cells showed no change in cell cycle 
distribution of viable cells, although there was an increase 
in the pre-G1 population in IGF-1R post-inhibited cells 
compared with TMZ alone (Figure 4D). To check whether 
this represented increased apoptosis, we assessed caspase 
activation by western blot (Figure 4E). TMZ alone 
generated little positive signal in either cell line, with an 
increase on addition of OSI-906, particularly upon post-
treatment in A375M. We also probed for DNA damage 
marker γH2AX, noting that relative γH2AX signals in 
OSI-906 pre, co- and post- treated A375M cells (Figure 4E 
left) paralleled the pattern of relative chemo-sensitization 
(Figure 3D), with more intense signal upon IGF-1R post-
inhibition. In CHL1, where sequencing did not influence 
chemo-sensitivity, IGF-1Ri did not influence TMZ-
induced γH2AX (Figure 4E right).
The γH2AX western blot suggested possible 
excess DNA damage in A375M cells treated with OSI-
906 after TMZ. Although principally induced by DSBs, 
non-focal γH2AX can be induced by other processes 
including apoptosis [25, 26]. Therefore, we assessed 
immunofluorescent γH2AX foci formed at sites of DSBs. 
Testing 72 hr post-TMZ to parallel cell cycle and western 
Figure 3: IGF-1R inhibition induces schedule-dependent sensitization to TMZ. A. A375M, B. CHL1 cells were treated with 
solvent, OSI-906 or TMZ. Graphs: mean ± SEM % survival from n = 2 assays, each with triplicate dishes (6 data points). Cell survival was 
inhibited in both cell lines by 250 μM TMZ and by OSI-906 at 300–1000 nM in A375M, and 30–1000 nM in CHL1 (*p < 0.05, ***p < 
0.001). C. Treatment schedules for chemo-sensitivity testing. D. A375M cells treated simultaneously or sequentially with solvent, 30–300 
nM OSI-906 and/or TMZ. Graphs: mean ± SEM % survival from n = 3 assays, showing significance of differences from control (OSI-906-
untreated) cultures (*p < 0.05, **p < 0.01, ***p < 0.001). Legends: TMZ SF50 (μM) at each OSI-906 concentration.
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blotting data, we detected γH2AX foci in TMZ-treated 
cells (Figure 4F), and quantified changes in cells exposed 
to TMZ alone or with pre-, co- or post- treatment with 
OSI-906, as Figure 3C. As a single agent, TMZ induced 
more foci in CHL1 than A375M cells (Supplementary 
Figure S4C), consistent with relative TMZ sensitivities 
in viability assays (Table 1). There was no difference 
in TMZ-induced foci in IGF-1Ri-treated A375M or 
CHL1 cells at this 72 hr time-point (Supplementary 
Figure S4C). In light of the cell cycle changes seen 
previously (Figure 4C), and the time needed to generate 
toxic DSBs, we repeated this assessment 120 hr post-
TMZ. Here, we observed significant reduction in TMZ-
induced γH2AX foci in A375M cells pre- or co-treated 
with OSI-906 compared with cells treated with TMZ alone 
or TMZ followed by OSI-906 (Figure 4G, left). These 
findings suggest reduced induction of DNA damage as 
a consequence of G1 accumulation of IGF-1R pre- or 
co- inhibited cells. In contrast, IGF-1R inhibition did 
not influence TMZ-induced γH2AX foci in CHL1 cells 
(Figure 4G, right), in which there were no sequence-
dependent changes in TMZ-sensitization (Supplementary 
Figure S3) or cell cycle distribution (Figure 4D).
OSI-906 enhances sensitivity of melanoma 
xenografts to temozolomide
To explore the therapeutic potential of these data, 
we tested whether OSI-906 is tolerable with TMZ in 
vivo, employing the sequential (TMZ → OSI-906) 
schedule identified as optimal in vitro (Figure 3D), and 
using A375M, known to be tumorigenic in vivo [27]. To 
mimic clinical treatment, TMZ was dosed on days 1–5 
in Ora-Plus, as previously tested in glioblastoma [28]. 
Figure 4: IGF-1R inhibition pre-TMZ induces G1 arrest and reduces DSB induction. A. Cells were treated with 300 nM 
OSI-906 and IGF-1 as Figure 1D. B. A375M cells treated with solvent, 300 nM OSI-906 or 300 μM TMZ. After 72 hr, cell cycle profiles 
were determined by analysis of BrdU incorporation vs DNA content (PI staining). C. A375M, D. CHL1 cells treated with solvent, 300 nM 
OSI-906, 300 μM TMZ alone or with 300 nM OSI-906 applied 24 hr before, simultaneously or 24 hr post-TMZ, and collected 72 hr 
post-TMZ. Graphs: mean ± SEM data from n = 4 analyses in each cell line. Compared with TMZ alone, TMZ-treated/IGF-1R-inhibited 
cells showed significant differences in pre-G1, G1 and non-cycling S populations of A375M, and only in the pre-G1 population of CHL1 
(*p < 0.05, **p < 0.01, ***p < 0.001). E. Cultures treated as C, D were lysed 72 hr post-TMZ for western blotting. F. CHL1 cells were 
treated with solvent or 300 μM TMZ and after 72 hr stained for γH2AX. G. Cells were treated as C), D) and after 120 hr, 50–2300 cells per 
condition were analysed for γH2AX foci. Graphs: mean ± SEM % cells with > 3 foci. Pre- or co- inhibition of IGF-1R significantly reduced 
TMZ-induced foci in A375M (*p < 0.05, **p < 0.01 compared with TMZ alone).
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After 5 days, TMZ-treated mice were divided into 
groups for IGF-1Ri dosing (Supplementary Figure S5A). 
OSI-906 is insoluble in aqueous solution, and has been 
previously dosed in tartaric acid [29]. In case this acid 
solvent could exacerbate toxicity, we compared OSI-
906 administration in tartaric acid, Ora-Plus or corn oil 
(Figure 5A). TMZ and OSI-906 were tolerable when 
administered sequentially with weight loss generally 
<10%, with the exception of OSI-906 in tartaric acid 
(~12.5%), although OSI-906-treated groups were not 
significantly different (Supplementary Figure S5A–S5B). 
TMZ induced a trend to tumor growth delay (Figure 5A, 
Supplementary Figure S5C), but this experiment was 
not powered to detect differences in tumor volume. Four 
hours after final OSI-906 dosing, blood and tumor were 
collected for immunohistochemical and pharmacokinetic 
analysis. Ki67 positivity was detectable in all tumors, 
with evidence of reduction in the TMZ-alone group 
(Figure  5B, 5C), paralleling the reduced S-phase fraction 
in cell cycle analysis (Figure 4C). Activated caspase 3 was 
clearly detectable in tumors treated with TMZ followed 
by OSI-906, but not in vehicle or TMZ alone groups 
(Figure 5B–5C). OSI-906 dosing achieved drug levels in 
tumor of 3700 – 5700 ng/ml (8.7 – 13.6 μM), and plasma 
of ~4000 – 5600 ng/ml (9.3 – 13.3 μM; Figure 5D), 
corresponding to plasma levels achieved clinically 
Figure 5: IGF-1R inhibition sensitizes melanoma to TMZ in vivo. A. Mice bearing A375M xenografts were treated with Ora-
Plus (OP, Group A, 2 mice) or 50 mg/kg TMZ in Ora-Plus by gavage days 1–5 (Group B, 8 mice). On day 6, group B was randomly divided 
into 4 groups of 2 for gavage on days 6–8 with 50 mg/kg OSI-906 in 25 mM tartaric acid (TA, B1), Ora-Plus (OP, B2), corn oil (CO, B3), 
or vehicle (Ora-Plus) alone (B4). Graph: mean ± range tumor volume (% baseline). B. Tumors harvested 4 hr after final OSI-906 dosing 
were stained for Ki67 and activated caspase 3. Scale bar 50 μm. C. Quantification of Ki67 (white bars) and activated caspase 3 (black bars). 
Ki67 counts were lower in group B4 (TMZ alone; *p < 0.05, **p < 0.01). Activated caspase 3 was detected only in tumors treated with TMZ 
followed by OSI-906. D. OSI-906 levels in plasma and tumors. Dotted line: steady state OSI-906 levels achieved at recommended Phase 
2 dose [18]. OSI-906 levels in groups A (control) and B4 (TMZ alone) were below limits of quantitation: ~20 ng/ml (0.05 μM) for plasma, 
200 ng/g (0.5 μM) for tumor. E. Mice bearing A375M xenografts were treated with Ora-Plus (control), 50 mg/kg TMZ (T), 50 mg/kg OSI-
906 (O) or combination treatment, scheduling OSI-906 to avoid administration immediately before/with TMZ. Graph: mean ± SEM tumor 
volumes, n = 6. F. Graph: linear regression analysis of slopes of tumor growth, showing individual data points and mean ± SEM slope as % 
control. There were no differences in growth rates of control, TMZ or OSI-906 –treated tumors, and significant reduction in the combination 
group compared with each of the other groups (*p < 0.05, **p < 0.01).
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[18, 19]. Ora-Plus was chosen to administer both TMZ 
and OSI-906, to assess effects on tumor growth.
Mice bearing A375M xenografts were treated with 
vehicle (Ora-Plus) alone, TMZ, OSI-906, or both drugs, 
using clinically relevant schedules, dosing TMZ on 
days 1–5 and OSI-906 on three days per week [1, 18]. 
This intermittent schedule allowed us to adopt the drug-
sequencing regimen (TMZ → OSI-906) that was more 
effective in vitro (Figure 3D). After a second cycle of 
TMZ, OSI-906 dosing continued on a D1–3 q7 day cycle 
(Figure 5E). Both TMZ and OSI-906 induced weight loss 
<10%, which in the case of OSI-906 was rapid onset, 
unaccompanied by distress, and recovering rapidly on 
days off-treatment (Supplementary Figure S5D). Effects on 
tumor growth are shown in Figure 5E. Untreated control 
tumors grew rapidly, achieving a volume of 1000 mm3 in 
29 ± 2 days from the start of treatment. TMZ or OSI-906 
caused minor growth delay, taking 36 ± 6 and 39 ± 5 days 
respectively to reach 1000 mm3, not significantly different 
from controls (Supplementary Figure S5E). Combination 
treatment induced significant growth delay, tumors taking 
79 ± 4 days to attain 1000 mm3 (p < 0.001 compared with 
the other groups, Supplementary Figure S5E). Growth 
delay was also evident when evaluating the gradient of 
tumor growth (Figure 5F), which was reduced by TMZ 
or OSI-906 by 13% and 25% respectively compared 
with controls. If additive, combination treatment would 
induce 38% reduction; the observed reduction was 78%, 
suggesting supra-additivity. Furthermore, survival was 
prolonged by the combination treatment compared with 
the other three groups (Supplementary Figure S5F). These 
results suggest that OSI-906 can be administered with TMZ 
to xenograft-bearing mice, and effects on melanoma growth 
are supra-additive compared with either agent alone.
DISCUSSION
Our results indicate that human melanoma cell 
lines show variable sensitivity to IGF-1Ri, consistent 
with data from large drug screens in which A375 and 
SKmel2 were more sensitive to OSI-906 and A2058, 
CHL1 and SKmel28 more resistant [30]. Here, some cell 
lines showed potent inhibition of proliferation and cell 
survival at clinically-achievable OSI-906 concentrations. 
Indeed, the Phase 1 study of continuous oral dosing of 
OSI-906 reported an objective partial response, converted 
by surgery into a highly durable complete response, in 
one of 3 melanoma patients [19]. In the current study, 
responses to OSI-906 were unrelated to levels of total or 
activated IGF-1R, consistent with clinical findings that 
IGF-1R expression does not predict sensitivity to IGF-
1R inhibition [31]. The most sensitive cell lines (501mel, 
A375, A375M; Table 1) harbor V600E BRAF; supporting 
activity in the context of activating RAS-RAF mutations, 
a study of synthetic lethal interactions identified 
IGF-1R as a key driver of AKT phosphorylation in KRAS 
mutant NSCLC [32]. In addition, we noted that in the 
melanoma cell lines and an isogenic NSCLC model, 
loss of WT p53 correlated with resistance to IGF-1R 
inhibition. The association of WT p53 with sensitivity to 
IGF-1R inhibition was also reported using the non-ATP-
competitive IGF-1R inhibitor picropodophyllin [33], and 
may be relevant in selecting patients for treatment with 
IGF-1R inhibitory drugs.
The melanoma cell lines were relatively TMZ 
resistant, with GI50 and SF50 values above the clinical 
Cmax [1]. Our results indicate a correlation between 
intrinsic TMZ resistance and IGF-1R activation, and 
show that two different small molecule IGF-1R inhibitors 
sensitize human melanoma cells to TMZ. Both IGF-
1Ri agents used here also inhibit INSR, and it would be 
informative to measure INSR expression in the melanoma 
cell line panel, to assess the contribution of this receptor 
to chemo-resistance. IGF-1R inhibitors have also been 
shown to enhance TMZ-sensitivity in neuroblastoma 
and medulloblastoma [34, 35]. These and other studies 
implicated IGF-1R as a mediator of chemo-resistance 
via regulation of AKT activation, cell cycle progression 
and cell survival [34–36]. In our study, IGF-1R-inhibited 
melanoma cells showed enhanced TMZ-induced apoptosis, 
relatively minor at 24–48 hr, more substantial 72 hr post-
TMZ in vitro, and much more striking in melanoma 
xenografts after 5 days of TMZ and 3 days of OSI-906 
(Figure 5B, 5C). These differences could reflect the greater 
dependence on IGF-1R for anchorage-independent 3D vs 
2D growth [37], and/or the more prolonged time-course of 
the in vivo experiment.
In addition to regulating apoptosis, two additional 
mechanisms may be relevant to IGF-1R-mediated 
chemo-resistance. Firstly, cytotoxic drugs are reported to 
induce IGF-1R activation, which can be suppressed by 
IGF-1R inhibition [38]. Secondly, there is evidence from 
our group and others that a functional IGF-1R is required 
for DSB repair by HR, which is required for the repair 
of replication-associated DSBs induced by TMZ [12, 13, 
39, 40]. However, combining IGF-1Ri with phase-specific 
chemotherapy raises concerns that sensitization to TMZ 
could be antagonized by delayed cell cycle progression 
in IGF-1R-inhibited cells. While we found no evidence 
of antagonism, we did observe more effective chemo-
sensitization in vitro using sequential (TMZ → OSI-
906) application (Figure 3D). We found no evidence that 
IGF-1R inhibition influenced removal of TMZ adducts 
(Supplementary Figure S2B–S2E), or delayed resolution 
of TMZ-induced DNA damage foci (Figure 4G), in 
contrast to the delayed repair of radiation-induced DSBs 
we reported recently [13]. There was, however, evidence 
that IGF-1R pre-inhibition caused accumulation of cells 
in G1, and reduced the subsequent yield of toxic TMZ-
induced γH2AX foci (Figure 4C, 4G). Co-application 
of IGF-1R inhibitor showed the same phenotype, which 
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is logical given the delay in induction of TMZ-induced 
DSBs. We also noted that the differences in γH2AX signal 
on western blot of A375M cells (Figure 4E, left) appeared 
to be more marked than the changes in γH2AX foci 
(Figure 4G), possibly implicating other processes such as 
apoptosis or replication stress that induce γH2AX [25].
Previous studies have recognized that delayed cell 
cycle progression induced by targeted agents including 
IGF-1Ri show potential to protect tumors against phase 
specific cytotoxic drugs [29, 41]. To our knowledge this 
protective effect has not until now been confirmed to 
be associated with reduced accumulation of toxic DNA 
damage. Unfortunately, this potential for antagonism has 
not been taken into account in the design of previous 
trials of IGF-1Ri with chemotherapy, and could have 
compromised outcomes in previous studies combining 
long half-life IGF-1R antibodies with phase-specific 
cytotoxic drugs [42–44]. Of potential relevance, we note 
that both A375M and CHL1 cells harbor mutant CDKN2A, 
which encodes mutant p16INK4a with reduced capacity to 
inhibit the cyclin D1/CDK4 complex that regulates the G1 
to S transition [45]. Despite this, A375M cells responded 
to IGF-1Ri with accumulation in G1. While CHL1 cells 
were chemo-sensitized by IGF-1Ri, this effect did not vary 
with sequence, and nor did they show sequence-related 
changes in cell cycle distribution. It is possible that lack 
of schedule-dependence in this cell line could be due to 
the presence of mutant p53, while A375M cells harbour 
WT p53, and/or a reflection of the lesser sensitivity of 
CHL1 cells to IGF-1R inhibition. Although CHL1 cells 
did not show sequence-dependent differences in chemo-
sensitivity, post-TMZ inhibition of IGF-1R was as 
effective as pre- or co- treatment. Therefore, the cytotoxic 
→ IGF-1Ri sequence is preferred for future studies. Our 
data confirm that this sequential combination treatment 
regimen is tolerable in vivo, inducing supra-additive 
inhibition of melanoma xenograft growth, using doses and 
schedules of both drugs consistent with clinical use [1, 18].
In summary, our data support the concept that 
the IGF axis is an important mediator of therapy 
resistance. By exploiting interactions between the cell 
cycle, DNA damage response and apoptosis induction, 
IGF1R inhibition can be an effective route to chemo-
sensitization. Our findings also highlight the importance 
of scheduling when combining IGF-1R inhibitory drugs 
and other targeted agents with cytotoxic drugs that induce 
replication-associated DNA damage.
MATERIALS AND METHODS
Cell lines and reagents
Melanoma cell lines CHL1, SKmel2, HMCB were 
from American Type Culture Collection, A375, A357M, 
501mel and COLO858 from Professor Colin Goding 
(Ludwig Institute for Cancer Research Oxford), SKmel28 
and A2058 from Cancer Research UK Cell Services, and 
SKmel23 from Professor Vincenzo Cerundolo (Weatherall 
Institute of Molecular Medicine Oxford). Subline B231 
of H1299 p53 null non-small cell lung cancer (NSCLC) 
cells that express tetracycline-inducible wild-type p53 
[20] was from Professor Xin Lu (Ludwig Institute for 
Cancer Research, Oxford). All cell lines were negative 
for mycoplasma (MycoAlert kit, Lonza Rockland Inc, 
Rockland US). AZ3801 and OSI-906 were provided 
by Elaine Kilgour (AstraZeneca) and Elizabeth Buck 
(OSI Pharmaceuticals/Astellas) respectively. TMZ was 
synthesized as described [46] and stored at +4oC protected 
from light. For in vitro use, 10 mM stock solutions of 
AZ3801, OSI-906, TMZ and O6BG (Sigma) in DMSO 
were aliquoted and stored at -20oC. Each agent was freshly 
diluted in culture medium to the correct final concentration. 
OSI-906 was freshly-prepared as a 10x stock in pre-warmed 
culture medium containing 10% FCS and 5% DMSO. 
Control cultures were treated with DMSO without drug.
Western blotting, assays for viability, cell 
survival and apoptosis
CellTiter Glo (Promega) viability assays and 
clonogenic assays were performed as in reference [13], using 
cultures growing in full medium supplemented with 10% 
FCS. Western blotting was performed as described [13], 
using antibodies to: IGF-1R (#3027, Cell Signaling 
Technology, CST), phospho-Y1135/6 IGF-1R (#3024, CST), 
phospho-S473 AKT (#4051, CST), total AKT (#9272, CST), 
phospho-T202/Y204 ERK 1/2 (#4377, CST), total ERK 
1/2 (#4695, CST), MGMT (#557045, BD Pharmingen), 
p53 (#9282, CST) PARP (#9542, CST) and actin (ab8224 
or ab8227, Abcam). For each western blot shown, similar 
results were obtained in 1–2 further independent replicates. 
Viability and survival data were graphed and curve-fitted 
(GraphPad Prism v5) to interpolate GI50 and SF50 values 
(drug concentrations that suppress growth or survival to 50% 
of control values). Apoptosis was quantified by Apo-ONE® 
Homogenous Caspase 3/7 Assay (Promega).
Assays for MGMT, AAG, O6-meG and N7-meG
MGMT and AAG activity assays were based on 
cleavage of 32P labelled oligonucleotides containing single 
O6-meG or ethenoadenine residues as described [47, 48]. 
O6-meG levels in cellular DNA were determined by a 
modification of the MGMT activity assay [47] and levels 
of N7-meG adducts in cellular DNA were determined by 
an immunoslot blot method [49].
Cell cycle analysis and immunofluorescence
Cell cycle analysis and detection of γH2AX 
foci were performed according to [13, 50]. Cells were 
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pulsed with 10 μM 5-bromo-2′-deoxyuridine (BrdU; 
Sigma-Aldrich) for 30 min. Floating and adherent cells 
were collected, centrifuged at 250 g for 5 min and fixed in 
ice-cold 70% ethanol. After repeat centrifugation, cells 
were incubated in 2M HCl containing 0.1 mg/ml pepsin 
at 23oC for 20 min, washed with PBS and then with 2% 
FCS in PBS. Cells were resuspended in 2% FCS in PBS 
with αBrdU antibody (clone B44, BD Biosciences, 1:100) 
for 90 min at 23oC. After adding 2% FCS in PBS, the cells 
were pelleted again, resuspended in 2% FCS in PBS with 
Alexa Fluor 488 goat anti-mouse secondary antibody (Life 
Technologies, 1:200), and incubated for 60 min at 23oC in 
the dark. The cells were washed in PBS and resuspended 
in PBS containing 10 μg propidium iodide and 10 μl 
RNase (20 mg/ml, 70 U/ml; Invitrogen). After 15 min 
incubation at 23oC, samples were analyzed on a Becton 
Dickinson FACScan using FlowJo v 8.8.7 software.
For immunofluorescent detection of γH2AX foci, 
cells were fixed with 4% paraformaldehyde with 0.1% 
Triton-X-100 in PBS for 10 min, permeabilized in 0.3% 
Triton-X-100 in PBS for 10 min and blocked in 3% BSA 
in PBS for 40 min. Cells were incubated overnight at 
4°C with antibody to S139 γH2AX (#05–636, Upstate/
Millipore), diluted 1:1000 in 3% BSA in PBS. After 
washing in PBS, bound antibody was detected with 
secondary antibody conjugated to Alexa Fluor 488 
(InVitrogen; 1:1000 in 3% BSA) and incubated for 
one hour at 23oC in the dark. Cells were DAPI-stained, 
images were acquired on an IN Cell Analyzer 1000 (GE 
Healthcare) and analysed using IN Cell Analysis 3.5 
software (GE Healthcare).
Xenograft studies
In vivo work was carried out at Biomedical Services, 
John Radcliffe Hospital Oxford under a Home Office 
approved Project License. Xenografts were established 
by injecting 107 A375M cells with matrigel (BD 
Biosciences) into the flanks of 6–7 week old female Balb/c 
immunodeficient (nu/nu) mice. Tumors were measured 
2–3 times a week, volumes were calculated as π(length 
x width x height)/6, and mice were randomly allocated 
to treatment groups when tumor volumes reached 100–
200 mm3. Treatments were prepared fresh each day, 
administered by gavage as a suspension of 2.5 mg/ml 
TMZ or OSI-906. Mice were weighed daily when on 
treatment to adjust dosing to 50 mg/kg, otherwise weekly. 
For initial tolerability and PK testing, mice were treated 
with 50 mg/kg TMZ in Ora-Plus (Fagron UK) on days 
1–5, followed on days 6–8 by 50 mg/kg OSI-906 in Ora-
Plus, 25 mM tartaric acid or corn oil. Controls were treated 
with Ora-Plus. Four hours after final OSI-906 dosing, the 
experiment was terminated, whole blood was obtained 
under anesthetic by cardiac puncture, and plasma was 
stored at –80oC. Tumors were halved for snap-freezing in 
liquid nitrogen, and formalin-fixation. OSI-906 levels in 
plasma and frozen tumor were analyzed by Andy Cooke 
and Mark Bittner (OSI Pharmaceuticals, Boulder CO). 
To test effects on tumorigenicity, mice were randomly 
allocated to four groups for dosing with Ora-Plus (control), 
TMZ on days 1–5 and 28–30, and/or OSI-906 on a three 
day per week schedule. Mice were sacrificed when tumors 
reached license limits or for loss of ≥20% baseline weight. 
Formalin-fixed, paraffin-embedded 4 μm xenograft 
sections were stained using antibodies to Ki67 (clone 
SP6, #VP-RM04, Vector Laboratories, 1:400 dilution) and 
active Caspase 3 (#AF835, R&D Systems, 1:1500). Ki67 
positive nuclei were counted in 8 high-powered fields 
(0.25 mm2) for each section, and caspase 3 by the intensity 
(0–3 scale) and proportion (0–4) of positive staining, to 
generate Intensity x Percentage scores (IPS; 0–12).
Statistical analysis
Data were analyzed using GraphPad Prism v5, using 
t-tests to compare 2 groups, one-way ANOVA for multiple 
groups, Spearman correlation for association between 
variables, and linear regression to compare xenograft 
growth rates.
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